ImmunoPrecise Antibodies Ltd. Stock price Toronto S.E.
Equities
IPA
CA45257F2008
Pharmaceuticals
Sales 2024 * | 24.59M 18.15M | Sales 2025 * | 29.82M 22.01M | Capitalization | 54.13M 39.95M |
---|---|---|---|---|---|
Net income 2024 * | -12M -8.86M | Net income 2025 * | -9M -6.64M | EV / Sales 2024 * | 2.2 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.82 x |
P/E ratio 2024 * |
-4.33
x | P/E ratio 2025 * |
-5.87
x | Employees | 102 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.44% |
Latest transcript on ImmunoPrecise Antibodies Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 18-02-20 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 23-09-28 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 23-09-04 |
Jennifer Bath
CEO | Chief Executive Officer | - | 18-02-20 |
1st Jan change | Capi. | |
---|---|---|
+0.44% | 90.78B | |
+9.61% | 43.96B | |
-16.67% | 31.34B | |
+44.99% | 23.45B | |
-9.42% | 16.48B | |
-25.92% | 15.03B | |
-9.27% | 12.79B | |
-7.57% | 12.19B | |
+0.07% | 8.5B |